The name of the patent is "a new peptide to prevent fat accumulation and a pharmaceutical composition for the prevention or treatment of obesity comprising the same."
This patent technology was developed in collaboration with the National University of Seoul and relates to a pharmaceutical composition for the prevention or treatment of obesity based on a peptide to inhibit fat accumulation. This peptide inhibits the differentiation of mesenchymal stem cells into adipocytes and inhibits the accumulation of adipose tissue so that it can be used to prevent or treat obesity.
In women, estrogen levels decrease after menopause, accumulating abdominal fat and causing complications such as osteoporosis and diabetes.
An employee of the company said: "Sibutramine, a generic remedy for appetite suppressants, is used as an antidepressant and most of the appetite suppressants are used as antidepressants." This drug causes various side effects, also causes non-alcoholic fatty liver disease. "
Presently, preclinical studies on peptide-based non-alcoholic midwifes are in progress and this new US patent will be resistant to research into diseases related to fat metabolism. "Until now, it is known that there is no cure for non-alcoholic disease.
Meanwhile, Naive is a biotechnology company that develops biometric fusion materials based on peptides for tissue regeneration, tissue regeneration, and drugs for the treatment of inflammatory diseases. Recently, as the aging society has become more aggressive, Prepared for clinical entry.[디지털뉴스국 김규리 기자][ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]